Terms of service

<!DOCTYPE html> <html lang="en"> <head> <title>Terms of service</title> <meta name="description" content="Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Puma has been focused on developing the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. Puma believes that neratinib has clinical applications in the treatment of several other cancers as well, including non-small cell lung cancer and other solid tumor types that over-express or have a mutation in HER2. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Puma commenced commercial sales of the drug in 2017 and it is marketed in the United States as NERLYNX® tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. Commercial sales commenced in the European Union in 2019. Puma has entered into additional exclusive license agreements with various parties to commercialize NERLYNX in regions outside the United States, including the European Union, Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma plans to continue to pursue the commercialization of NERLYNX outside the United States. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib has been tested in Clinical Trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Puma initially intends to focus the development of alisertib on the treatment of patients with metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer. Alan H. Auerbach has served as Chairman of the Board, CEO and President of Puma Biotechnology, Inc. since he founded the Company in 2010. Prior to Puma, Mr. Auerbach served as CEO, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from its inception in 2003 until its acquisition by Johnson & Johnson in July 2009. From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of J&J), providing leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone (Zytiga) was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the EU in September 2011. Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and mid-cap biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific and clinical due diligence, and selected biotechnology companies followed by the company. In 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-cap biotechnology companies. Prior to his work as a securities analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented Clinical Trials in the field of oncology. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Puma Biotechnology, Inc., founded in 2010, is headquartered in Los Angeles, California. Additional information may be found at https://www.pumabiotechnology.com. NERLYNX® is a registered trademark of Puma Biotechnology, Inc." /> <meta name="keywords" content="Puma Biotechnology, biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, early stage, metastatic, drug development, pb272, Clinical Trials, oncology, her2+, biopharmaceutical, in-licensing, cancer treatment, oncology, extended adjuvant therapy, non-small cell lung cancer, biliary cancer, ExteNET, SUMMIT, FB-10 , CONTROL, NALA, tyrosine kinase inhibitor, TBCRC-022, HER2-mutated, EGFR, EGFR exon 18, EGFR exon 18-mutant, HER-Seq, alisertib, aurora kinase A, adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A, inhibitor of aurora kinase A, disruption of mitosis, apoptosis of rapidly proliferating tumor cells, apoptosis of tumor cells, breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, acute myeloid leukemia, metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer, HER2-negative breast cancer, ER-positive breast cancer" /> <meta name="author" content="Puma Biotechnology, Inc." /> <meta charset="UTF-8" /> <meta name="format-detection" content="telephone=no" /> <link rel="stylesheet" href="./css/style.min.css?_v=20240926104104" /> <link rel="shortcut icon" href="favicon.ico" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <script async src="https://kit.fontawesome.com/ee8e128eea.js?_v=20240914195904" crossorigin="anonymous"></script> </head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-CN3D3P6NW6"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-CN3D3P6NW6'); </script> <script> const PATH = 'img/'; </script> <body> <div class="wrapper"> <header class="header" data-lp> <div class="header__container"> <div class="header__content"> <a href="./index.html" class="header__logo"> <picture> <source srcset="./img/logo.webp" type="image/webp" /> <img src="./img/logo.png" data-no-lazy width="299" height="102" aria-label="Puma Biotechnology Logo" alt="Puma Biotechnology Logo" /> </picture> </a> <div class="header__menu menu"> <button type="button" class="menu__icon icon-menu" aria-label="Open menu button"><span></span></button> <nav class="menu__body"> <ul class="menu__list"> <li class="menu__item"><a href="./" class="menu__link">Home</a></li> <li class="menu__item"> <a href="./about/overview.html" class="menu__link">About</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./about/overview.html">Overview</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./about/leadership.html">Leadership Team</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./about/bod.html">Board of Directors</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./about/cg.html">Corporate Governance</a> </li> </ul> </li> <li class="menu__item"> <a href="./product/product.html" class="menu__link">Product</a> </li> <li class="menu__item"> <a href="./pipeline/pipeline.html" class="menu__link">Pipeline</a> </li> <li class="menu__item"> <a href="./clinical-trials/clinincal_trials.html" class="menu__link">Clinical Trials</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./clinical-trials/alisca_lung1.html">ALISCA™-Lung1</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./clinical-trials/alisca_breast1.html">ALISCA™-Breast1</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./clinical-trials/cds.html">Clinical Data Sharing</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./clinical-trials/eap.html">Extended Access Program</a> </li> </ul> </li> <li class="menu__item"> <a href="news/news.html" class="menu__link">News</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="news/latest_news.html">Latest News Release</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="news/news-archive.html">Archives</a> </li> </ul> </li> <li class="menu__item"> <a href="./investors/events_webcasts.html" class="menu__link">Investors</a> <ul class="menu__sublist"> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/news-releases/default.aspx" target="_blank">News Releases</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="./investors/events_webcasts.html">Events and Webcasts</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx" target="_blank">SEC Filings</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-faqs/default.aspx" target="_blank">Investor FAQs</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/stock-information/default.aspx" target="_blank">Stock Information</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/stock-information/default.aspx#stock-historical" target="_blank">Stock Lookup</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-email-alerts/default.aspx" target="_blank">Stock Alerts</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/analyst-coverage/default.aspx" target="_blank">Analyst Coverage</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/annual-reports-and-proxies/default.aspx" target="_blank">Annual Meeting</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/sec-filings/all-filings/default.aspx" target="_blank">Legal Notices</a> </li> <li class="menu__item"> <i class="fa-solid fa-chevron-right"></i> <a href="https://investor.pumabiotechnology.com/resources/investor-contacts/default.aspx" target="_blank">Contacts</a> </li> </ul> </li> <li class="menu__item"> <a href="./contacts/contacts.html" class="menu__link">Contacts</a> </li> <li class="menu__item"> <a href="#" class="menu__link" data-popup=".third-website" data-popup-redirect="https://phf.tbe.taleo.net/phf03/ats/careers/v2/jobSearch?act=redirectCwsV2&cws=37&org=PUMABIOTECH">Careers</a> </li> </ul> </nav> </div> </div> </div> </header> <main class="page page--legal"> <section class="page__news news"> <div class="news__container"> <div class="news__top"> <h2 class="news__title title">Legal Notice</h2> </div> <div class="news__body"> <h2 class="news__title">Terms of service</h2> <div class="single-post"> <div class="single-post__content"> <p><b>Last Updated/Effective Date: March 01, 2024</b></p> <p> Welcome to the Terms of Service (these “Terms”) for the websites, https://www.pumabiotechnology.com/, https://investor.pumabiotechnology.com/, https://nerlynx.com/, https://www.reducerecurrence.com/, and https://nerlynxhcp.com/ (the <b>“Websites”</b>), operated on behalf of Puma Biotechnology, Inc. (<b>“Company”</b>, <b>“we”</b> or <b>“us”</b>). The Websites and any content, tools, features, and functionality offered on or through our Websites are collectively referred to as the <b>“Services”</b>. </p> <p> These Terms govern your access to and use of the Services. Please read these Terms carefully, as they include important information about your legal rights. By accessing and/or using the Services, you are agreeing to these Terms. If you do not understand or agree to these Terms, please do not use the Services. </p> <p> For purposes of these Terms, “you” and “your” means you as the user of the Services. If you use the Services on behalf of a company or other entity, then “you” includes you and that entity, and you represent and warrant that (a) you are an authorized representative of the entity with the authority to bind the entity to these Terms, and (b) you agree to these Terms on the entity’s behalf. </p> <ol class="custom-marker-list"> <li>1 Who May Use the Services You must be 18 years of age or older and reside in the United States or any of its territories to use the Services. By using the Services, you represent and warrant that you meet these requirements.</li> <li>2 Location of Our Privacy Policy</li> <li> 2.1 Privacy Policy. Our Privacy Policy describes how we handle the information you provide to us when you use the Services. For an explanation of our privacy practices, please visit our Privacy Policy located at <a href="https://pumabiotechnology.com/privacy_policy.html">https://pumabiotechnology.com/privacy_policy.html</a>. </li> <li>3 Rights We Grant You</li> <li> 3.1 Right to Use Services. We hereby permit you to use the Services for your personal non-commercial use only, provided that you comply with these Terms in connection with all such use. If any software, content or other materials owned or CONTROLled by us are distributed to you as part of your use of the Services, we hereby grant you a personal, non-assignable, non-sublicensable, non-transferrable, and non-exclusive right and license to access and display such software, content and materials provided to you as part of the Services, in each case for the sole purpose of enabling you to use the Services as permitted by these Terms. Your access and use of the Services may be interrupted from time to time for any of several reasons, including, without limitation, the malfunction of equipment, periodic updating, maintenance, or repair of the Service or other actions that Company, in its sole discretion, may elect to take. </li> <li> 3.2 Restrictions On Your Use of the Services. You may not do any of the following in connection with your use of the Services, unless applicable laws or regulations prohibit these restrictions or you have our written permission to do so: <ol> <li> download, modify, copy, distribute, transmit, display, perform, reproduce, duplicate, publish, license, create derivative works from, or offer for sale any information contained on, or obtained from or through, the Services, except for temporary files that are automatically cached by your web browser for display purposes, or as otherwise expressly permitted in these Terms; </li> <li>duplicate, decompile, reverse engineer, disassemble, or decode the Services (including any underlying idea or algorithm), or attempt to do any of the same;</li> <li>use, reproduce or remove any copyright, trademark, service mark, trade name, slogan, logo, image, or other proprietary notation displayed on or through the Services;</li> <li>exploit the Services for any commercial purpose, including without limitation communicating or facilitating any commercial advertisement or solicitation;</li> <li>access or use the Services in any manner that could disable, overburden, damage, disrupt, or impair the Services or interfere with any other party’s access to or use of the Services or use any device, software, or routine that causes the same;</li> <li>attempt to gain unauthorized access to, interfere with, damage, or disrupt the Services, or the computer systems or networks connected to the Services;</li> <li>circumvent, remove, alter, deactivate, degrade, or thwart any technological measure or content protections of the Services;</li> <li> use any robot, spider, crawlers, scraper, or other automatic device, process, software, or queries that intercepts, “mines”, scrapes, extracts, or otherwise accesses the Services to monitor, extract, copy, or collect information or data from or through the Services, or engage in any manual process to do the same; </li> <li>introduce any viruses, trojan horses, worms, logic bombs, or other materials that are malicious or technologically harmful into our systems;</li> <li>violate any applicable law or regulation in connection with your access to or use of the Services; or</li> <li>access or use the Services in any way not expressly permitted by these Terms.</li> </ol> </li> <li><b>4 Ownership and Content</b></li> <li> 4.1 Ownership of the Services. The Services, including their “look and feel” (e.g., text, graphics, images, logos), proprietary content, information, and other materials, are protected under copyright, trademark, and other intellectual property laws. You agree that the Company and/or its licensors own all right, title and interest in and to the Services (including any and all intellectual property rights therein) and you agree not to take any action(s) inconsistent with such ownership interests. We and our licensors reserve all rights in connection with the Services and its content, including, without limitation, the exclusive right to create derivative works. </li> <li> 4.2 Ownership of trademarks. The Company’s name, the Company’s logo and all related names, logos, product and service names, designs, and slogans are trademarks of the Company or its affiliates or licensors. Other names, logos, product and service names, designs, and slogans that appear on the Services are the property of their respective owners, who may or may not be affiliated with, connected to, or sponsored by us. </li> <li> 4.3 Ownership of Feedback. We welcome feedback, comments, and suggestions for improvements to the Services (“Feedback”). You acknowledge and expressly agree that any contribution of Feedback does not and will not give or grant you any right, title, or interest in the Services or in any such Feedback. All Feedback becomes the sole and exclusive property of the Company, and the Company may use and disclose Feedback in any manner and for any purpose whatsoever without further notice or compensation to you and without retention by you of any proprietary or other right or claim. You hereby assign to the Company any and all right, title, and interest (including, but not limited to, any patent, copyright, trade secret, trademark, show-how, know-how, moral rights and any and all other intellectual property right) that you may have in and to any and all Feedback. </li> <li>5 Third Party Services and Materials</li> <li> 5.1 Use of Third Party Materials in the Services. Certain Services may display, include, or make available content, data, information, applications, or materials from third parties (“Third Party Materials”) or provide links to certain third party websites. By using the Services, you acknowledge and agree that the Company is not responsible for examining or evaluating the content, accuracy, completeness, availability, timeliness, validity, copyright compliance, legality, decency, quality, or any other aspect of such Third Party Materials or websites. We do not warrant or endorse and do not assume and will not have any liability or responsibility to you or any other person for any third-party services, Third Party Materials, or third-party websites, or for any other materials, products, or services of third parties. Third Party Materials and links to other websites are provided solely as a convenience to you. </li> <li>6 Disclaimers, Limitations of Liability and Indemnification</li> <li> 6.1 <span>Disclaimers.</span> <ol> <li> Your access to and use of the Services are at your own risk. You understand and agree that the Services are provided to you on an “AS IS” and “AS AVAILABLE” basis. Without limiting the foregoing, to the maximum extent permitted under applicable law, the Company, its parents, affiliates, related companies, officers, directors, employees, agents, representatives, partners, and licensors (the “<b>the Company Entities</b>”) DISCLAIM ALL WARRANTIES AND CONDITIONS, WHETHER EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. The Company Entities make no warranty or representation and disclaim all responsibility and liability for: (a) the completeness, accuracy, availability, timeliness, security, or reliability of the Services; (b) any harm to your computer system, loss of data, or other harm that results from your access to or use of the Services; (c) the operation or compatibility with any other application or any particular system or device; and (d) whether the Services will meet your requirements or be available on an uninterrupted, secure or error-free basis. No advice or information, whether oral or written, obtained from the Company Entities or through the Services, will create any warranty or representation not expressly made herein. </li> <li> HE LAWS OF CERTAIN JURISDICTIONS, INCLUDING THE STATE OF NEW JERSEY, DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES AS SET FORTH IN SECTION 6.2 BELOW. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MAY HAVE ADDITIONAL RIGHTS. </li> <li>THE COMPANY ENTITIES TAKE NO RESPONSIBILITY AND ASSUME NO LIABILITY FOR ANY CONTENT THAT YOU, ANOTHER USER, OR A THIRD PARTY CREATES, UPLOADS, POSTS, SENDS, RECEIVES, OR STORES ON OR THROUGH OUR SERVICES.</li> <li>YOU UNDERSTAND AND AGREE THAT YOU MAY BE EXPOSED TO CONTENT THAT MIGHT BE OFFENSIVE, ILLEGAL, MISLEADING, OR OTHERWISE INAPPROPRIATE, NONE OF WHICH THE COMPANY ENTITIES WILL BE RESPONSIBLE FOR.</li> </ol> </li> <li> 6.2 <span>Limitations of Liability.</span> TO THE EXTENT NOT PROHIBITED BY LAW, YOU AGREE THAT IN NO EVENT WILL THE COMPANY ENTITIES BE LIABLE (A) FOR DAMAGES OF ANY KIND, INCLUDING INDIRECT, SPECIAL, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, LOSS OF USE, DATA, OR PROFITS, BUSINESS INTERRUPTION OR ANY OTHER DAMAGES OR LOSSES, ARISING OUT OF OR RELATED TO YOUR USE OR INABILITY TO USE THE SERVICES), HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER UNDER THESE TERMS OR OTHERWISE ARISING IN ANY WAY IN CONNECTION WITH THE SERVICES OR THESE TERMS AND WHETHER IN CONtrACT, StrICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) EVEN IF THE COMPANY ENTITIES HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE, OR (B) FOR ANY OTHER CLAIM, DEMAND, OR DAMAGES WHATSOEVER RESULTING FROM OR ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OR THE DELIVERY, USE, OR PERFORMANCE OF THE SERVICES. THE COMPANY ENTITIES’ TOTAL LIABILITY TO YOU FOR ANY DAMAGES FINALLY AWARDED SHALL NOT EXCEED THE GREATER OF ONE HUNDRED DOLLARS ($100.00), OR THE AMOUNT YOU PAID THE COMPANY ENTITIES, IF ANY, IN THE PAST SIX (6) MONTHS FOR THE SERVICES (OR OFFERINGS PURCHASED ON THE SERVICES) GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATIONS WILL APPLY EVEN IF THE ABOVE STATED REMEDY FAILS OF ITS ESSENTIAL PURPOSE. </li> <li> 6.3 <span>Indemnification</span>. By entering into these Terms and accessing or using the Services, you agree that you shall defend, indemnify, and hold the Company Entities harmless from and against any and all claims, costs, damages, losses, liabilities, and expenses (including attorneys’ fees and costs) incurred by the Company Entities arising out of or in connection with: (a) your violation or breach of any term of these Terms or any applicable law or regulation; (b) your violation of any rights of any third party; (c) your misuse of the Services; or (d) your negligence or wilful misconduct. If you are obligated to indemnify any Company Entity hereunder, then you agree that Company (or, at its discretion, the applicable Company Entity) will have the right, in its sole discretion, to CONTROL any action or proceeding and to determine whether Company wishes to settle, and if so, on what terms, and you agree to fully cooperate with Company in the defence or settlement of such claim. </li> <li>7 <b>Additional Provisions</b></li> <li> 7.1 <span>Updating These Terms</span>. We may modify these Terms from time to time in our sole discretion without obligation of prior notice in which case we will update the “Last Revised” date at the top of these Terms. If we make changes that are material, we will use reasonable efforts to attempt to notify you, such as by e-mail and/or by placing a prominent notice on the first page of the Websites. However, it is your sole responsibility to review these Terms from time to time to view any such changes material or otherwise. The updated Terms will be effective as of the time of posting, or such later date as may be specified in the updated Terms. Your continued access or use of the Services after the modifications have become effective will be deemed your acceptance of the modified Terms. </li> <li> 7.2 <span>Termination of License</span>. If you breach any of the provisions of these Terms, all licenses granted by the Company will terminate automatically. All sections which by their nature should survive the termination of these Terms shall continue in full force and effect subsequent to and notwithstanding any termination of these Terms by the Company or you. Termination will not limit any of the Company’s other rights or remedies at law or in equity. </li> <li> 7.3 <span>Injunctive Relief</span>. You agree that a breach of these Terms will cause irreparable injury to the Company for which monetary damages would not be an adequate remedy and the Company shall be entitled to equitable relief in addition to any remedies it may have hereunder or at law without a bond, other security, or proof of damages. </li> <li> 7.4 <span>California Residents</span>. If you are a California resident, in accordance with Cal. Civ. Code § 1789.3, you may report complaints to the Complaint Assistance Unit of the Division of Consumer Services of the California Department of Consumer Affairs by contacting them in writing at 1625 North Market Blvd., Suite N 112 Sacramento, CA 95834, or by telephone at (800) 952-5210. </li> <li> 7.5 <span>Forward-Looking Statements</span>. Some of the information presented or otherwise used in connection with the Services may contain certain projections or other forward-looking statements regarding future events or the future financial performance of the Company. Words such as “expects,” “plans,” “believes,” “goals,” “continues,” “may,” and other variations of such words and similar expressions identify forward-looking statements. In addition, any statements that refer to or may imply future financial performance, the Company’s anticipated growth, and trends in its businesses, and other characterizations of future events or circumstances, are forward-looking statements. All such statements that are not historical facts are based on the Company’s current expectations and are subject to a number of risks and uncertainties, and the actual events or results may differ materially. Please refer to the Company’s filings with the Securities and Exchange Commission, specifically, the Company’s most recent earnings release and its most recent Form 10-Q or Form 10-K for more information on the risk factors that could cause the actual results to differ materially from those contained in the Company’s forward-looking statements, including, among others, any adverse impact on the Company’s business or the global economy and financial markets, any changes in the Company’s product candidates’ regulatory approvals, results from the Company’s Clinival Trials, any litigation involving the Company and any changes to the Company’s in-licensed intellectual property. </li> <li> 7.6 <span>Miscellaneous</span>. If any provision of these Terms shall be unlawful, void, or for any reason unenforceable, then that provision shall be deemed severable from these Terms and shall not affect the validity and enforceability of any remaining provisions. These Terms and the licenses granted hereunder may be assigned by the Company but may not be assigned by you without the prior express written consent of the Company. No waiver by either party of any breach or default hereunder shall be deemed to be a waiver of any preceding or subsequent breach or default. The section headings used herein are for reference only and shall not be read to have any legal effect. The Services are operated by us in the United States. Notwithstanding Section 1, those who choose to access the Services from locations outside the United States do so at their own initiative and are responsible for compliance with applicable local laws. These Terms are governed by the laws of the State of California, without regard to conflict of laws rules, and the proper venue for any disputes arising out of or relating to any of the same will be the state and federal courts located in Los Angeles County, California. </li> <li> 7.7 <span>How to Contact Us</span>. You may contact us regarding the Services or these Terms at: 10880 Wilshire Blvd., Suite 2150, Los Angeles, CA 90024, by phone at 844-PUMABIO (786-2246) or by e-mail at <a href="mailto:info@pumabiotechnology.com">info@pumabiotechnology.com</a>. </li> </ol> </div> </div> </div> </div> </section>  <button type="button" class="back-top" data-goto=".wrapper"> <div class="back-top__icon"><i class="fa-solid fa-arrow-up"></i></div> <span class="back-top__text">Back to top</span> </button> </main> <footer class="footer"> <div class="footer__container"> <div class="footer__top"> <div class="footer__info"> <a href="./index.html" class="footer__logo" ><picture ><source srcset="img/logo.webp" type="image/webp" /> <img src="img/logo.png" width="140" height="48" alt="Awesome image" /></picture ></a> <div class="footer__col"> <h3 class="footer__label">About Us</h3> <ul class="footer__menu"> <li class="footer__item-menu"><a href="./about/overview.html">Overview</a></li> <li class="footer__item-menu"><a href="./about/leadership.html">Leadership team</a></li> <li class="footer__item-menu"><a href="./about/bod.html">Board of Directors</a></li> <li class="footer__item-menu"><a href="./about/cg.html">Corporate Governance</a></li> </ul> </div> </div> <div class="footer__social"> <h3 class="footer__label">Get in touch</h3> <ul class="footer__social-list">  <li class="footer__social-item"> <a href="#" aria-label="Follow us on LinkedIn" data-popup=".third-website" data-popup-redirect="https://www.linkedin.com/company/puma-biotechnology-ltd" target="_blank"><i class="fa-brands fa-linkedin"></i></a> </li> </ul> </div> </div> <div class="footer__contacts" data-da=".footer__top, 768, 1"> <h3 class="footer__label">Contact</h3> <div class="footer__line"> <div class="footer__row"> <h4 class="footer__caption">Puma Biotechnology, Inc.</h4> <p> Los Angeles, California <br /> 424-248-6500 Main </p> </div> <div class="footer__row"> <h4 class="footer__caption">Medical Information:</h4> 1-844-MED-PUMA (1-844-633-7862), or <br /> <a href="mailto:medinfo@pumabiotechnology.com">medinfo@pumabiotechnology.com</a> </div> <div class="footer__row"> <h4 class="footer__caption">Business Development:</h4> <p> <a href="mailto:info@pumabiotechnology.com">info@pumabiotechnology.com</a> </p> </div> <div class="footer__row"> <h4 class="footer__caption">investor Relations:</h4> <a href="mailto:ir@pumabiotechnology.com">ir@pumabiotechnology.com</a> </div> </div> </div> <div class="footer__bottom"> <p class="footer__copyright">© 2024 Puma Biotechnology, Inc.</p> <ul class="footer__menu footer__menu--row"> <li class="footer__item-menu"><a href="./privacy_policy.html">Privacy Policy</a></li> <li class="footer__item-menu"><a href="./wa_pp.html">WA Privacy Policy</a></li> <li class="footer__item-menu"><a href="./tos.html">Terms of Service</a></li> <li class="footer__item-menu"><a href="./data_rights_request.html">Data Rights Request</a></li> <li class="footer__item-menu"><a href="./legal_notice.html">Legal Notices</a></li> <li class="footer__item-menu"><a href="./site_map.html">Site Map</a></li> </ul> </div> </div> </footer> </div> <div id="popup" aria-hidden="true" class="popup third-website"> <div class="popup__wrapper"> <div class="popup__content"> <button data-close type="button" class="popup__close">Close</button> <div class="popup__text"> <h3>NOTICE: You are leaving our website</h3> <p> When you click on the button below, you will leave our website and will enter a website maintained by a third party that is not related to Puma Biotechnology, Inc. We are providing a link to the third party's website solely as a convenience to you, because we believe that website may provide useful content. We are not, by referring or linking to the third party website, incorporating its contents into our own website. We do not endorse or guarantee, and we disclaim any responsibility for the content, products or services offered on that website; its performance or interaction with your computer; its security and privacy policies and practices; and any consequences that may result from visiting that website. </p> <p> By clicking on the button below, you acknowledge and agree to everything we say above. <a class="popup__go-back" data-popup-redirect-target href="#"><span>Continue</span></a> </p> <p> You can also click on the link below to return to the Puma Biotechnology, Inc. website. <a class="popup__go-back" href="#"><span>Go Back</span></a> </p> </div> </div> </div> </div> <div aria-hidden="true" class="popup succes"> <div class="popup__wrapper"> <div class="popup__content"> <button data-close type="button" class="popup__close"> <svg width="20" height="20"> <use xlink:href="img/icons/icons.svg#svg-close"></use> </svg> </button> <div class="popup__thanks"> <h2>Thank you!</h2> <p>Your message was sent.</p> </div> </div> </div> </div> <script src="js/app.min.js?_v=20240926104104"></script> </body> </html>

CINXE.COM

Terms of service